Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humlin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients.

Trial Profile

Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humlin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Hyaluronidase; Insulin; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 02 Oct 2009 Results have been presented at EASD 2009, according to a Halozyme Therapeutics media release.
    • 29 May 2009 Interim results reported at ADA 2009, as reported in a Halozyme media release.
    • 19 Mar 2009 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top